{"anticipatedPostingDate":"2027-03","denomUnitsSelected":"Participants","description":"ORR: % of participants with objective response. sCR: CR \\& normal sFLC ratio and absence of clonal cells in BMB/BMA by immunohistochemistry or immunofluorescence. CR: negative immunofixation on serum and urine, disappearance of soft tissue plasmacytomas \\&\\<5% plasma cells in BMA. If disease measurable by sFLC only, preceding criteria \\&normal sFLC ratio. VGPR: Serum and urine M-protein detectable by immunofixation but not on electrophoresis; or \\>=90% reduction in serum M-protein \\& urine M-protein level \\<100 mg/24h; PR: \\>=50% reduction of serum M-protein \\& reduction in 24h urinary M-protein by \\>=90% or to \\<200 mg/24 hours (If disease measurable by sFLC only: VGPR \\& PR: \\>=90% \\&\\>=50% decrease in difference respectively between involved \\& uninvolved sFLC levels). In addition, if present at baseline, VGPR \\& PR: \\>=90% \\&\\>=50% reduction compared with baseline in soft tissue plasmacytomas' size.","reportingStatus":"NOT_POSTED","timeFrame":"From treatment initiation till study completion","title":"SSB: ORR as Per IMWG Criteria as Determined by Investigator- Phase 1b Dose Escalation","type":"SECONDARY"}